Supplementary Table 1.

(1)

Variable Placebo (n=8)

Eplerenone

(n=7) P-value

Serum creatinine, mg/dL 1.37 ± 0.16 1.83 ± 0.14 0.05

eGFR, ml/min/1.73m² 58.9 [38.4-91.2] 39.5 [37.8-57.5] 0.256

Glucose, mg/dL 135.8 ± 27 142.0 ± 13 0.844

UPCR, mg/g 1817 ± 396 1341 ± 362 0.396

UACR, mg/g 1509 ± 342 1033 ± 271 0.304

RR systolic, mmHg 145 ± 7 137 ± 9 0.516

RR diastolic, mmHg 85 ± 7 82 ± 6 0.742

Hemoglobin, g/dL 13.2± 1 13.0 ± 0.7 0.838

Sodium, mmol/L 140 ± 0.9 141 ± 0.6 0.358

Potassium, mmol/L 4.7 ± 0.1 4.8 ± 0.1 0.524

Calcium, mmol/L 2.33 ± 0.0 2.28 ± 0.0 0.366

Phosphate, mmol/L 1.2 [1.1-1.2] 1.1 [0.8-1.2] 0.268

Protein, g/L 70.8 ± 1.8 66.2 ± 1.6 0.087

Albumin, g/L 41.9 ± 1.0 42.1 ± 1.9 0.936

PTH, pg/mL 71.7± 12.1 87.5 ± 16.4 0.451

25-OH Vitamin D, nmol/L 34.4[21.0-77.6] 37 [24.7-86.2] 0.761 1,25-OH Vitamin D, pg/mL 38[22.0-61.0] 21.0 [32.0-42.0] 0.736

Beta blocker, n (%) 2 (29) 0 (0) n.a

Calcium channel antagonist, n (%) 1 (14) 0 (0) n.a.

Supplementary Table 1.

Baseline laboratory values and antihypertensive therapy at study inclusion. eGFR, estimated glomerular filtration rate; UPCR, urinary protein/creatinine ratio; UACR, urinary albumin/creatinine ratio; RR, blood pressure; PTH, parathyroid hormone.